VIATRIS INC. (VTRS) Gross Margin
- Gross margin · 12 months: Value 34.93%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 34.93% | Gross profit / revenue. Period ending 2026-06-30. $5.13B ÷ $14.69B × 100 ≈ 34.93% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 5.13B USD | Gross Profit |
| Revenue | 14.69B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 9.60B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $5.13B | $14.69B | $9.60B | 34.93% |
| 2026-03-31 | $5.01B | $14.52B | $9.55B | 34.51% |
| 2025-12-31 | $5.01B | $14.25B | $9.29B | 35.18% |
| 2025-09-30 | $5.08B | $14.08B | $9.04B | 36.10% |
| 2025-06-30 | $5.17B | $14.07B | $8.95B | 36.74% |
| 2025-03-31 | $5.28B | $14.28B | $9.05B | 36.97% |
| 2024-12-31 | $5.62B | $14.69B | $9.12B | 38.27% |
| 2024-09-30 | $6.01B | $15.00B | $9.04B | 40.03% |
| 2024-06-30 | $6.24B | $15.20B | $9.00B | 41.04% |
| 2024-03-31 | $6.40B | $15.32B | $8.96B | 41.77% |
| 2023-12-31 | $6.44B | $15.39B | $8.99B | 41.84% |
| 2023-09-30 | $6.12B | $15.43B | $9.35B | 39.64% |
| 2023-06-30 | $6.17B | $15.56B | $9.43B | 39.67% |
| 2023-03-31 | $6.27B | $15.76B | $9.53B | 39.77% |
| 2022-12-31 | $6.50B | $16.22B | $9.77B | 40.06% |
| 2022-09-30 | $6.77B | $16.68B | $9.96B | 40.58% |
| 2022-06-30 | $6.59B | $17.14B | $10.59B | 38.49% |
| 2022-03-31 | $6.22B | $17.59B | $11.43B | 35.35% |
| 2021-12-31 | $5.58B | $17.81B | $12.31B | 31.30% |
| 2021-09-30 | $4.74B | (m) | $12.43B | (m) |
| 2021-06-30 | $4.32B | (m) | $11.28B | (m) |
| 2021-03-31 | $4.02B | (m) | $9.74B | (m) |
| 2020-12-31 | $3.80B | $11.82B | $8.15B | 32.12% |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-09-27 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-06-28 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2020-03-29 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) |
| 2019-09-29 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.00B | $11.27B | $7.43B | 35.51% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |